Nanjing Hicin Pharmaceutical Co., Ltd. (SHE:300584)
30.20
-0.52 (-1.69%)
Jun 11, 2026, 1:05 PM CST
SHE:300584 Revenue
Nanjing Hicin Pharmaceutical had revenue of 160.34M CNY in the quarter ending March 31, 2026, with 12.40% growth. This brings the company's revenue in the last twelve months to 688.74M, up 26.97% year-over-year. In the year 2025, Nanjing Hicin Pharmaceutical had annual revenue of 671.05M with 33.05% growth.
Revenue (ttm)
688.74M
Revenue Growth
+26.97%
P/S Ratio
5.35
Revenue / Employee
1.25M
Employees
553
Market Cap
3.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 671.05M | 166.69M | 33.05% |
| Dec 31, 2024 | 504.36M | -13.47M | -2.60% |
| Dec 31, 2023 | 517.83M | -8.63M | -1.64% |
| Jan 1, 2023 | 526.47M | -51.85M | -8.97% |
| Jan 1, 2022 | 578.32M | -127.98M | -18.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.16B |
| Jinhe Biotechnology CO., LTD. | 2.99B |
| Bide Pharmatech | 1.35B |
| Tibet Weixinkang Medicine | 1.16B |
| LanZhou Foci Pharmaceutical | 910.98M |
| Shandong Wohua Pharmaceutical | 818.16M |
| Newland Pharmaceutical | 659.54M |
| Shanghai Xiao Fang Pharmaceutical | 541.90M |